Erlotinib in combined therapy of common lung adenocarcinoma in the presence of EGFR gene mutation

The article presents data on the efficacy of erlotinib in the treatment of NSCLC in the presence of EGFR gene mutation. Its advantages over chemotherapy in terms of survival, quality of life, and tolerability of treatment, both as monotherapy and in combination with cytostatics and other targeted dr...

Full description

Saved in:
Bibliographic Details
Main Authors: S. V. Orlov, A. M. Lozhkina, S. V. Odintsova, M. A. Sviridenko, A. O. Cheremnykh, M. A. Urtenova, E. A. Filippova
Format: Artigo
Language:Russo
Published: Remedium Group LLC 2019-06-01
Series:Медицинский совет
Subjects:
lung cancer
egfr mutations
erlotinib
Online Access:https://www.med-sovet.pro/jour/article/view/3054
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items